Cyclooxygenase-2 expression and its association with vascular endothelial growth factor, microvessel density and clinicopathologic characteristics of colorectal carcinoma
DOI:
https://doi.org/10.3329/bjp.v11iS1.26410Keywords:
Colorectal carcinoma, Cyclooxygenase-2 expression, Micorvessel density, Vascular endothelial growth factorAbstract
The aim of this study was to investigate the expression of cyclooxygenase type-2 (COX-2) and its association with angiogenesis and clinicopathologic characteristics of colorectal carcinoma (CRC). COX-2 expression was detected by means of immunohistochemistry in a series of human tissue samples with CRC (n = 120), dysplasia tissue closely adjacent to carcinomas (n = 40) and normal colorectal mucosa (n = 40), and their expressions association with vascular endothelial growth factor (VEGF), CD31-labeled micorvessel density(MVD) in CRC and other clinicopathologic characteristics were investigated. The expression of COX-2 in CRC tissues (78.3%) was obviously higher than that in adjacent tissue and normal mucosal tissue (p<0.01). COX-2 expression was correlated significantly with the grading, advanced cancer, Dukes stage and lymph node metastasis, distant metastasis and VEGF (p<0.05). Our result demonstrates that COX-2 expression was significantly higher in earlier stages of CRC. It can be suggested that COX-2 expression may be important in the initial development of CRC. The findings of the present study suggest that COX-2 overexpression in CRC may be considered as a negative prognostic marker.
Downloads
1424
711 Read
307
References
Al-Maghrabi J, Buhmeida A, Emam E, Syrjänen K, Sibiany A, Al-Qahtani M, Al-Ahwal M. Cyclooxygenase-2 expression as a predictor of outcome in colorectal carcinoma. World J Gastroenterol. 2012; 18: 1793-99.
Dixon DA, Blanco FF, Bruno A, Patrignani P. Mechanistic aspects of COX-2 expression in colorectal neoplasia. Recent Results Cancer Res. 2013; 191: 7-37.
Kelly LM, Hill AD, Kennedy S, Connolly EM, Ramanath R, Teh S, Dijkstra B, Purcell R, McDermott EW, O'Higgins N. Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol. 2003; 29: 707-10.
Kopczy?ska E, makarewicz R. Endoglin: A marker of vascular endothelial cell proliferation in cancer. Wspolczesna onkol. 2012; 16: 68-71.
Koyama Y, Okayama H, Kumamoto K, Saito K, Nakamura I, Ohki S, Takenoshita S. Overexpression of endoglin (CD105) is associated with recurrence in radically resected gastric cancer. Exp Ther Med. 2010; 1: 627-33.
Lavalle GE, bertagnolli AC, tavares WLF, Cassali GD. Cox-2 expression in canine mammary carcinomas: Correlation with angiogenesis and overall survival. Vet Pathol. 2009; 46: 1275-80.
Miglietta A, Toselli M, Ravarino N, Vencia W, Chiecchio A, Bozzo F, Motta M, Torchio B, Bocca C. COX-2 expression in human breast carcinomas: Correlation with clinicopathological features and prognostic molecular markers. Expert Opin Ther Targets. 2010; 14: 655-64.
Miladi-Abdennadher I, Abdelmaksoud-Dammak R, Ayed-Guerfali DB, Ayadi L, Khabir A, Amouri A, Frikha F, Tahri N, Ellouz S, Frikha M, Sellami-Boudawara T, Mokdad-Gargouri R. Expression of COX-2 and E-cadherin in Tunisian patients with colorectal adenocarcinoma. Acta Histochem. 2012; 114: 577-81.
Peng L, Zhou Y, Wang Y, Mou H, Zhao Q. Prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: A meta-analysis of the literature. PLoS One. 2013; 8: e58891.
Ranger GS, Jewell A, Thomas V, Mokbel K. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers. J Surg Oncol. 2004; 88: 100-03.
Thielemann A, Baszczuk A, Kopczy?ski Z, Kopczy?ski P, Grodecka-Gazdecka S. Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer. Ann Agric Environ Med. 2013, 20: 293-97.
Thorat D, Sahu A, Behera R, Lohite K, Deshmukh S, Mane A, Karnik S, Doke S, Kundu GC. Association of osteopontin and cyclooxygenase?2 expression with breast cancer subtypes and their use as potential biomarkers. Oncol Lett. 2013; 6: 155964.
Wang G, Qin Y, Zhang J, Zhao J, Liang Y, Zhang Z, Qin M, Sun Y. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Int J Mol Sci. 2014; 15: 9546-65.
Wang GP, Qin MH, Liang YA, Zhang H, Zhang ZF. The significance of biomarkers in nipple discharge and serum in diagnosis of breast cancert. In: Advanced Engineering and Technology. Liquan Xie, Dianjian Huang (eds.). CRC Press, 2014, pp 66571.
Wang JJ, Sun XC, Hu L, Liu ZF, Yu HP, Li H, Wang SY, Wang DH. Endoglin (CD105) expression on microvessel endothelial cells in juvenile nasopharyngeal angiofibroma: Tissue microarray analysis and association with prognostic significance. Head Neck. 2013; 35: 1719-25.
Yi C, Zhang Y, Yu Z, Xiao Y, Wang J, Wang J, Qiu H, Yu W, Tang R, Yuan Y, Guo W, Deng W. Melatonin enhances the anti-tumor effect of fisetin by inhibiting COX-2/iNOS and NF-kB/p300 signaling pathways. PLoS ONE. 2014; 9: e99943.
Additional Files
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
